Reunion Neuroscience (TSX:REUN) - Prezzo delle azioni, notizie e analisi

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

REUN Panoramica delle azioni

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. Maggiori dettagli

REUN analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Analisi del rischio

Prezzo delle azioni altamente volatile negli ultimi 3 mesi

Ha meno di 1 anno di pista di cassa

Si prevede che gli utili diminuiranno in media di 14% all'anno per i prossimi 3 anni

Realizza un fatturato inferiore a 1 milione di dollari ( CA$0 )

+ 2 più rischi

Reunion Neuroscience Inc. Concorrenti

Willow Biosciences

TSX:WLLW

CA$11.5m

Medicure

TSXV:MPH

CA$9.4m

COSCIENS Biopharma

TSX:CSCI

CA$13.3m

Covalon Technologies

TSXV:COV

CA$101.9m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Reunion Neuroscience
Prezzi storici delle azioni
Prezzo attuale dell'azione	CA$1.42
Massimo di 52 settimane	CA$9.44
Minimo di 52 settimane	CA$0.83
Beta	4.21
1Variazione di 1 mese	-2.07%
Variazione a 3 mesi	40.59%
Variazione di 1 anno	-72.95%
3Variazione a 3 anni	n/a
Variazione a 5 anni	n/a
Variazione dall'IPO	-89.48%

Notizie e aggiornamenti recenti

Recent updates

Here's Why Field Trip Health (TSE:FTRP) Must Use Its Cash Wisely

Aug 01

We're Keeping An Eye On Field Trip Health's (TSE:FTRP) Cash Burn Rate

Apr 03

Could The Field Trip Health Ltd. (CSE:FTRP) Ownership Structure Tell Us Something Useful?

Jan 17

Rendimenti per gli azionisti

	REUN	CA Biotechs	CA Mercato
7D	-3.4%	0.6%	1.7%
1Y	-73.0%	-4.6%	24.0%

Ritorno vs Industria: REUN ha avuto una performance inferiore rispetto al Canadian Biotechs che ha registrato un rendimento -4.6 % nell'ultimo anno.

Rendimento vs Mercato: REUN ha avuto una performance inferiore al mercato Canadian che ha registrato un rendimento 24 % nell'ultimo anno.

Volatilità dei prezzi

Is REUN's price volatile compared to industry and market?
REUN volatility
REUN Average Weekly Movement	18.6%
Biotechs Industry Average Movement	11.8%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.6%
10% least volatile stocks in CA Market	2.9%

Prezzo delle azioni stabile: Il prezzo delle azioni di REUN è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 19% ) di REUN è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni Canadian.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2008	16	Greg Mayes	reunionneuro.com

Reunion Neuroscience Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Reunion Neuroscience con la sua capitalizzazione di mercato?
REUN statistiche fondamentali
Capitalizzazione di mercato	CA$16.64m
Guadagni(TTM)	-CA$38.10m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-0.4x

Rapporto P/E

REUN è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
REUN Conto economico (TTM)
Ricavi	CA$0
Costo del fatturato	CA$0
Profitto lordo	CA$0
Altre spese	CA$38.10m
Guadagni	-CA$38.10m

Ultimi guadagni dichiarati

Mar 31, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-3.25
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	0%

Come si è comportato REUN nel lungo periodo?

Vedi performance storica e confronto

This company has been acquired

REUN Panoramica delle azioni

Analisi del rischio

Reunion Neuroscience Inc. Concorrenti

TSX:WLLW

CA$11.5m

TSXV:MPH

CA$9.4m

TSX:CSCI

CA$13.3m

TSXV:COV

CA$101.9m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

MPM Asset Management, L.L.C. acquired Reunion Neuroscience Inc. (TSX:REUN) in a going private transaction.

Reunion Neuroscience's Shares to Be De-Listed from the Toronto Stock Exchange on the Close of Markets on or Around August 2, 2023

New major risk - Financial position

MPM Asset Management, L.L.C. entered into a definitive arrangement agreement to acquire Reunion Neuroscience Inc. (TSX:REUN) for CAD 17.7 million in a going private transaction.

Reunion Neuroscience Inc., Annual General Meeting, Jul 12, 2023

Reunion Neuroscience Inc. to Report Q3, 2023 Results on Feb 14, 2023

Recent updates

MPM Asset Management, L.L.C. acquired Reunion Neuroscience Inc. (TSX:REUN) in a going private transaction.

Reunion Neuroscience's Shares to Be De-Listed from the Toronto Stock Exchange on the Close of Markets on or Around August 2, 2023

New major risk - Financial position

MPM Asset Management, L.L.C. entered into a definitive arrangement agreement to acquire Reunion Neuroscience Inc. (TSX:REUN) for CAD 17.7 million in a going private transaction.

Reunion Neuroscience Inc., Annual General Meeting, Jul 12, 2023

Reunion Neuroscience Inc. to Report Q3, 2023 Results on Feb 14, 2023

Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer

Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic Re104

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to CA$47.75

High number of new directors

Reunion Neuroscience Inc. to Report Q2, 2023 Results on Nov 14, 2022

High number of new and inexperienced directors

Reunion Neuroscience Inc. Appoints Edward Smith as Chief Financial Officer

Reunion Neuroscience Inc. Appoints Edward Smith as Chief Financial Officer

Reunion Neuroscience Inc. Announces Executive Changes

Reunion Neuroscience Inc. Appoints Greg Mayes as President

Consensus forecasts updated

High number of new and inexperienced directors

Field Trip Health Ltd., Annual General Meeting, Sep 29, 2022

Field Trip Health Ltd. completed the Split-Off of Field Trip Health & Wellness Ltd.

Field Trip Health Ltd. to Report Q1, 2023 Results on Aug 15, 2022

Here's Why Field Trip Health (TSE:FTRP) Must Use Its Cash Wisely

Price target increased to CA$14.25

Field Trip Health Ltd. Announces First Successful Dosings in the Phase 1 Clinical Study Entitled A Double-Blind

Field Trip Health Ltd. to Report Q4, 2022 Results on Jun 29, 2022

Price target decreased to CA$11.90

High number of new directors

Field Trip Health Ltd. Receives U.S. Patent Covering Novel Psychedelic Molecule FT-104

We're Keeping An Eye On Field Trip Health's (TSE:FTRP) Cash Burn Rate

High number of new and inexperienced directors

Consensus revenue estimates fall by 17%

Price target decreased to CA$11.90

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Field Trip Health Ltd. to Report Q3, 2022 Results on Feb 15, 2022

Field Trip Receives Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate), its Novel Psychedelic Molecule in Development

Field Trip Launches Site Management Organization Services

Second quarter 2022 earnings released: CA$0.23 loss per share (vs CA$0.16 loss in 2Q 2021)

Less than half of directors are independent

Less than half of directors are independent

Field Trip Health Ltd. to Pursue Treatment Resistant Depression and Postpartum Depression as Indications for FT-104

First quarter 2022 earnings released: CA$0.22 loss per share (vs CA$1.69 loss in 1Q 2021)

Full year 2021 earnings released: CA$0.70 loss per share (vs CA$2.03 loss in FY 2020)

Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch for FT-104, Its Novel Psychedelic Compound

Founder recently bought CA$250k worth of stock

Field Trip Health Ltd. has completed a Follow-on Equity Offering in the amount of CAD 82.875 million.

New 90-day high: CA$7.99

Field Trip Health Ltd. to Report Q3, 2021 Results on Feb 16, 2021

Could The Field Trip Health Ltd. (CSE:FTRP) Ownership Structure Tell Us Something Useful?

Field Trip Health Ltd. Announces Participation in a Maps-Sponsored Multi-Site Study of Mdma-Assisted Therapy to Treat Eating Disorders

Field Trip Health Ltd. has completed a Composite Units Offering in the amount of CAD 17.406 million.

Field Trip Health Ltd. to Report Q2, 2021 Results on Nov 30, 2020

Field Trip Health Ltd. and Whoop Announces Partnership to Measure Effect of Psychedelic Therapies on Physiology and Mental Health

Field Trip Health Ltd. Provides Update on FT-104

Heroic Hearts Project and Field Trip Health Ltd. Enter into A Strategic Relationship to Increase Legal Psychedelic Therapy Access for Military Veterans in North America

Field Trip Health Ltd. Announces Addition of Andrew Weil, M.D to Its Medical Advisory Board

Rendimenti per gli azionisti

Volatilità dei prezzi